OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained ...

Presenters highlight clinical insights and lessons from recent trial data and surgical experience On efficacy, Regillo said ...

New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year ...

REMAIN data show MCO-010 optogenetic therapy delivered durable ~3-line vision gains in retinitis pigmentosa regardless of ...

Initiating aflibercept 8 mg or faricimab as a first-line therapy was associated with longer treatment intervals and superior ...

An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen ...

A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, ...

Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038. According to an article published in Becker's Hospital Review, a number of medical ...

Introducing Nicholas Riina, MS. Nicholas Riina, MS, had his eye on the prize early on, growing up in a family in which he was ...

OLN324 outperformed faricimab on anatomic outcomes as early as week 1 in the JADE trial, with no cases of intraocular ...

Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 ...

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Brodie about ...